PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$12.1 -0.1  -0.6%

Last Trade - 4:45pm

Sector
Healthcare
Size
Small Cap
Market Cap £252.0m
Enterprise Value £197.6m
Revenue £n/a
Position in Universe 4201st / 7245

BRIEF-PDS Biotechnology Corp Achieves Safety Requirement Milestone For The First 12 Patients In Advanced Head And Neck Cancer

Mon 20th September, 2021 1:43pm
Sept 20 (Reuters) - PDS Biotechnology Corp  PDSB.O :
    * PDS BIOTECH ACHIEVES SAFETY REQUIREMENT MILESTONE FOR THE
FIRST
12 PATIENTS IN THE VERSATILE-002 PHASE 2 COMBINATION TRIAL OF
PDS0101-KEYTRUDA® IN ADVANCED HEAD AND NECK CANCER

Source text for Eikon:  ID:nGNX5GqyG3 
Further company coverage:  PDSB.O
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.